<SEC-DOCUMENT>0001193125-16-669717.txt : 20160803
<SEC-HEADER>0001193125-16-669717.hdr.sgml : 20160803
<ACCEPTANCE-DATETIME>20160803130056
ACCESSION NUMBER:		0001193125-16-669717
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160728
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160803
DATE AS OF CHANGE:		20160803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		161803102

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d236012d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of
earliest event reported) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;28, 2016 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting,&nbsp;Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19462</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (267)&nbsp;440-4200 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B></B><U>Item&nbsp;1.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Entry into a Material Definitive Agreement</U>.<B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;28, 2016, we received a
notice of termination of the Collaboration, Option and License Agreement by and between F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. and Inovio Pharmaceuticals, Inc., dated September&nbsp;9, 2013. The termination will be effective 90 days after
the notice date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;3, 2016, we issued a press release, which we file as Exhibit 99.1 to, and incorporate by reference in,
this Form 8-K current report as though fully set forth herein, announcing our plans to continue to develop our hepatitis B DNA vaccine (INO-1800) and independently advance our phase I study of INO-1800. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B></B><U>Item&nbsp;9.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>.<B> </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated August 3, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;3, 2016 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d236012dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236012g0803193325075.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>NEWS RELEASE </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immediate Release
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>CONTACTS:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, <U>bhertel@inovio.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, <U>jrichardson@inovio.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Inovio will Independently Develop Hepatitis B Immunotherapy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; August&nbsp;3, 2016 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the company will continue to develop its
hepatitis B DNA immunotherapy (INO-1800) independently following Roche&#146;s notice that it will discontinue its collaboration with Inovio and its development of INO-1800. INO-1800 was licensed to Roche from Inovio in 2013. All of Roche&#146;s
rights to INO-1800, including the right to license the product to other parties, will be returned. Inovio will continue to advance its current phase I study of INO-1800, which is enrolling as planned in 30 clinical sites in the U.S. and Asia-Pacific
regions. Inovio anticipates completing enrollment in the first half of 2017 and expects results in the second half of 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This randomized, open-label,
active-controlled, dose escalation study is evaluating the safety, tolerability, and immunogenicity of INO-1800, alone or in combination with INO-9112, Inovio&#146;s IL-12-based immune activator in adults with chronic hepatitis B infection. The
primary endpoints are safety and tolerability. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy&#146;s effect on several viral and antiviral parameters. All trial subjects are
also medicated with standard-of-care oral antiviral therapies. The study has completed interim safety reviews with a favorable safety profile to date. Immunology analyses are planned after completion of enrollment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s President&nbsp;&amp; CEO, said, &#147;While we acknowledge Roche&#146;s strategic decision in the area of hepatitis B,
we are optimistic that our potent immunotherapy platform will make a difference in this globally important chronic viral infection, similar to what we have demonstrated in HPV-related disease. Inovio was already managing the phase 1 clinical trial
so the study will continue on track without disruption.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INO-1800 for Hepatitis B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio has reported preclinical data showing its hepatitis B immunotherapy (INO-1800) generated strong T-cell and antibody responses that led to the
elimination of targeted liver cells in mice. Notably, researchers found that hepatitis B-specific T cells exhibited a killing function and could migrate to and stay in the liver and cause clearance of chronically infected cells without evidence of
liver injury. These results indicate that INO-1800 may have potential to treat chronic hepatitis B infection. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hepatitis B and Liver Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chronic infection with hepatitis B virus is one of the major causes and risk factors for liver cirrhosis and liver cancer. The virus is very infectious, with
over 240&nbsp;million people chronically infected worldwide. More than 60&nbsp;million of these people are at risk of the major complications of liver cirrhosis and liver cancer, which cause over 700,000 deaths globally each year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is taking
immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates
with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The
Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more
information, visit <U>www.inovio.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene
delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results
achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated,
that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to
support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial
milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the
conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into
partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or
devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s technology by potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, our Form 10-Q for the quarter ended&nbsp;March 31, 2016,&nbsp;and other
regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to
market licensed products, or that any of the forward-looking information provided herein will be proven accurate. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g236012g0803193325075.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g236012g0803193325075.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ 04# 2(  A$! Q$!_\0
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MRG(J6N/^'MI=VVD3-<*R1R/F-6&/J:["@ HHHH **** "BBB@ HHHH ****
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MY_XE\4:[HFLR6RF PL-\1,?5?SKG-ST"BL7POK1US1TN)-HG0[)0O3/K6U0
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MB2#*J2Y![X&:]EH A%G;*NT6\07TV"L#7?!MAJD#/;Q+;W0&59!@$^XKI:*
M/%-/OKSPUK>[!5XGV2Q_WAWKV:VN([NUBN(CE)%#*?8UYE\0[5(==CF4 &:(
M%OJ.*ZWP)<-/X7@#'/ELR#Z T =+1110 5Y=\1O^0_#_ -<!_,UZC7EWQ&_Y
M#\/_ %P'\S0!UW@;_D5K?_>;^=;\_P#Q[R?[A_E6!X&_Y%:W_P!YOYUOS_\
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H[CT-:5S:6]Y%Y5S!'*F<[77(I\44<$2QQ(J1J,!5& * 'T444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
